v for vendetta

Please log in or register before viewing unlimited contents in this forum.Thank you for visiting our webpage.

by administrators

v for vendetta

Kepada semua ahli, diminta untuk melakukan suai kenal didalam ruangan ICE-BREAKING untuk meluluskan status anda sebagai ahli,TQ

Latest topics

» my honda accord....
Mon Aug 10, 2009 12:43 pm by krullizme

» kebakaran hutan di bintulu
Thu Aug 06, 2009 11:58 pm by krullizme

» Kemalangan di jalan batu kitang
Thu Aug 06, 2009 11:51 pm by krullizme

» Seseorang yg benar2 mencintai kita....
Thu Aug 06, 2009 11:49 pm by krullizme

» upload la gambar2 member yg kena spotted...
Thu Aug 06, 2009 11:48 pm by krullizme

» kemalangan di jalan sultan tengah
Wed Aug 05, 2009 12:27 am by apex_4545

» pencuri ATM guna "bulldozer"??
Mon Aug 03, 2009 1:14 am by krullizme

» The Spring autoshow 2009
Sat Aug 01, 2009 3:44 am by krullizme

» tips mencari half-cut
Thu Jul 30, 2009 11:05 am by krullizme

Navigation

Affiliates


    vaksin H1N1

    Share
    avatar
    krullizme
    Administrator
    Administrator

    Posts : 188
    Join date : 2009-07-08
    Age : 27
    Location : kuching, sarawak

    Re: vaksin H1N1

    Post  krullizme on Tue Jul 28, 2009 1:59 am

    Rich countries corner supplies of swine flu vaccine
    PARIS — Governments are scrambling to buy up hundreds of
    millions of doses of swine flu vaccine but health experts warn the poor
    may lose out as wealthy countries corner strictly limited supplies.

    The World Health Organisation has unofficially estimated that the
    world’s labs may only be able to produce around 900 million doses for
    the A(H1N1) strain per year, for a planet that is home to 6.8 billion
    people.
    Global pharmaceutical companies are more optimistic about how much
    of the drug they can produce but, since each potential victim needs two
    doses, most of the world’s population will inevitably miss out.
    And there are already signs that the wealthiest countries will snap
    up more than their fair share in the rush to halt the outbreak, while
    Africa, Asia and Latin American will struggle to secure adequate
    amounts of vaccine.
    “The lion’s share of these limited supplies will go to wealthy
    countries. Again we see the advantage of affluence. Again we see access
    denied by an inability to pay,” WHO director Margaret Chan said last
    week.
    France, for example, placed a firm order for 94 million doses of
    vaccine doses and an option for 36 million more. Starting in October,
    it hopes to be able to protect each and every member of its population
    of 64 million.
    The United States has set aside at least a billion dollars to buy
    vaccine, and Britain hopes to protect at least half of its 60 million
    population by the start of next year and the other half as soon as
    possible afterwards.
    Australia has also ordered enough vaccine for its 21 million
    population, and as more rich world countries follow suit the world’s
    potential stock of the drug will soon run out, while prices are set to
    rise.
    “We expressed our concern about being able to count on the vaccine
    when it starts going on sale,” Argentina’s Health Minister Juan Manzur
    said last week after meeting worried Latin American colleagues.“We have information that much of the production is already reserved.”
    Pharmaceutical firms are racing to increase their capacity to
    produce an A(H1N1) vaccine, once tests confirm that one has been
    developed, and hope to begin releasing stocks in late September or
    early October.
    But even if they manage to make double the expected 900 million
    doses per year, this would still fall far short of the amount that
    would be needed to protect every man, woman and child on the planet
    from the pandemic.
    In these circumstances, some countries and independent experts think
    the best way forward is for authorities to focus on immunising health
    workers and the most vulnerable patients in order to conserve stocks.
    The WHO is negotiating with vaccine producers to secure donations or
    sales at lower prices for developing countries, while richer nations
    are being asked to donate some of their vaccine stocks.
    Peter Wutzler, president of the German Association for the Fight
    Against Viral Disease, said he thought his country had made the right
    decision in only looking to innoculate around a third of its people.
    “Vaccine for 30 percent of the population is enough to vaccinate the
    seven million people in the health sector, another seven million in the
    public service and risk groups such as pregnant women or children,” he
    told AFP.
    “Germany took account in its order of the fact that pharmaceutical
    groups have only a limited capacity. They will not be able to provide
    the whole world with the vaccine,” he warned.
    Even this more conservative plan, however, will eat up a large chunk
    of potential global stocks. Berlin ordered 50 million doses for 25
    million people and does not rule out ordering more if the situation
    worsens.
    “I think it is inappropriate that countries have sparked a competition for the vaccine,” said Wutzler.
    The swine flu virus has spread to almost every country in the world
    since it was discovered at the end of March. It was declared a global
    pandemic in June and is thought to have caused at least 800 deaths.
    While it spreads quickly, the A(H1N1) flu variant is so far not
    regarded as especially dangerous — the vast majority of victims survive
    and the illness responds to treatment from flu remedies such as Tamiflu.
    Experts warn, however, that the virus might mutate and become more
    deadly, and that with the onset of the winter flu season in the
    northern hemisphere might become a major health catastrophe.

      Current date/time is Tue Aug 21, 2018 7:28 pm